Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death (Q44153736)

30 November 2017

title

Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death (English)

1 reference

30 November 2017

C Katlama

1 reference

30 November 2017

J D Lundgren

1 reference

30 November 2017

O Kirk

1 reference

30 November 2017

A Mocroft

1 reference

30 November 2017

EuroSIDA study group

1 reference

30 November 2017

C Holkmann Olsen

1 reference

30 November 2017

S Vella

1 reference

30 November 2017

A Blaxhult

1 reference

30 November 2017

N Clumeck

1 reference

30 November 2017

M Fisher

1 reference

30 November 2017

A N Phillips

1 reference

30 November 2017

publication date

1 March 2007

1 reference

30 November 2017

1 reference

30 November 2017

1 reference

30 November 2017

1 reference

30 November 2017

page(s)

96-104

1 reference

Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

First-line therapy and mitochondrial damage: different nucleosides, different findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Adverse effects of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational c

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00436.X

10.1111/J.1468-1293.2007.00436.X

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference